News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,759 Results
Type
Article (14926)
Company Profile (299)
Press Release (266528)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79861)
Career Advice (163)
Deals (13343)
Drug Delivery (39)
Drug Development (50730)
Employer Resources (31)
FDA (5841)
Job Trends (5185)
News (145150)
Policy (10081)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21764)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6037)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4577)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (148)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43695)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1101)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4318)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1379)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31651)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51675)
Executive appointments (621)
FDA (7590)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (505)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6621)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (191)
Immuno-oncology (39)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7353)
IRA (12)
Job creations (870)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (131)
Medical device (2663)
Medtech (2672)
Mergers & acquisitions (6614)
Metabolic disorders (726)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26662)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20290)
Phase 3 (12844)
Pipeline (3240)
Policy (90)
Postmarket research (854)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1448)
Recruiting (12)
Regulatory (9902)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (344)
Last 30 days (1300)
Last 365 days (17836)
2026 (1651)
2025 (18105)
2024 (20554)
2023 (22425)
2022 (26831)
2021 (27818)
2020 (23370)
2019 (16243)
2018 (11757)
2017 (13760)
2016 (11854)
2015 (14351)
2014 (10395)
2013 (7489)
2012 (7545)
2011 (7619)
2010 (7431)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18263)
Australia (3110)
California (7075)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39179)
Florida (902)
Georgia (210)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5579)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1764)
North Carolina (825)
North Dakota (6)
Northern California (3474)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1278)
Puerto Rico (9)
Rhode Island (25)
South America (216)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23330)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (45)
281,759 Results for "voyager therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.
December 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Voyager Reports Third Quarter 2025 Financial and Operating Results
November 11, 2025
·
16 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
November 11, 2025
·
7 min read
Press Releases
Voyager to Present at Upcoming September 2025 Investor Conferences
August 26, 2025
·
2 min read
Press Releases
Voyager Reports Second Quarter 2025 Financial and Operating Results
August 7, 2025
·
14 min read
Press Releases
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
March 5, 2025
·
1 min read
Business
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer, effective July 8, 2024.
June 13, 2024
·
5 min read
Business
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported first quarter 2024 financial and operating results.
May 13, 2024
·
15 min read
Business
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024.
May 6, 2024
·
1 min read
1 of 28,176
Next
